China Biologic Products (NASDAQ:CBPO) Raised to Sell at BidaskClub

BidaskClub upgraded shares of China Biologic Products (NASDAQ:CBPO) from a strong sell rating to a sell rating in a research report released on Wednesday, December 20th.

Separately, Zacks Investment Research raised China Biologic Products from a sell rating to a hold rating in a report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $137.50.

China Biologic Products (NASDAQ:CBPO) traded up $3.87 during trading on Wednesday, hitting $81.37. The company had a trading volume of 198,181 shares, compared to its average volume of 233,667. The company has a market cap of $2,570.00, a P/E ratio of 21.19, a PEG ratio of 1.00 and a beta of 1.79. China Biologic Products has a 1-year low of $72.21 and a 1-year high of $120.46.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CBPO. Jennison Associates LLC grew its stake in shares of China Biologic Products by 0.8% during the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock worth $653,000 after purchasing an additional 44 shares during the period. Geode Capital Management LLC grew its stake in shares of China Biologic Products by 15.4% during the first quarter. Geode Capital Management LLC now owns 14,309 shares of the biopharmaceutical company’s stock worth $1,432,000 after purchasing an additional 1,906 shares during the period. Comgest Global Investors S.A.S. grew its stake in shares of China Biologic Products by 135.0% during the third quarter. Comgest Global Investors S.A.S. now owns 356,252 shares of the biopharmaceutical company’s stock worth $32,872,000 after purchasing an additional 204,649 shares during the period. Bank of New York Mellon Corp grew its stake in shares of China Biologic Products by 30.1% during the third quarter. Bank of New York Mellon Corp now owns 762,784 shares of the biopharmaceutical company’s stock worth $70,380,000 after purchasing an additional 176,325 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of China Biologic Products by 4.9% during the second quarter. Goldman Sachs Group Inc. now owns 61,404 shares of the biopharmaceutical company’s stock worth $6,945,000 after purchasing an additional 2,845 shares during the period. 65.13% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “China Biologic Products (NASDAQ:CBPO) Raised to Sell at BidaskClub” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://ledgergazette.com/2018/01/13/china-biologic-products-cbpo-upgraded-to-sell-by-bidaskclub.html.

China Biologic Products Company Profile

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply